Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.49 |
| ▸ | NQO2 | P16083 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878562 | 1.00 | ESR1 (0.57) | ESR1ESR2KMT2AMTNR1BMTNR1A | |
| SCHEMBL30878525 | 0.90 | ESR1 (0.57) | ESR1ESR2KMT2AMTNR1BSMN1; SMN2 | |
| SCHEMBL30878534 | 0.83 | ESR1 (0.58) | ESR1ESR2KMT2AMTNR1BSMN1; SMN2 | |
| SCHEMBL22145358 | 0.82 | ESR1 (0.45) | ESR1ESR2KMT2AMTNR1BSMN1; SMN2 | |
| SCHEMBL30878560 | 0.82 | ESR1 (0.53) | ESR1ESR2KMT2AMTNR1BSMN1; SMN2 | |
| SCHEMBL25722290 | 0.79 | SMN1; SMN2 (0.60) | KMT2AMTNR1BSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30878595 | 0.79 | DRD1 (0.55) | ESR1ESR2MTNR1B | |
| SCHEMBL33532809 | 0.78 | ESR1 (0.41) | ESR1ESR2KMT2AMTNR1B | |
| SCHEMBL30878596 | 0.78 | PDK2 (0.48) | ESR1ESR2MTNR1BMTNR1ANQO2 | |
| SCHEMBL25722288 | 0.78 | SMN1; SMN2 (0.58) | KMT2AMTNR1BSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| WO-2023106310-A1 | AROMATIC HETEROCYCLIC DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | 塩野義製薬株式会社 | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | ESR1 773/4885ESR2 1015/4885KMT2A 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.